# A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.

> **NCT07653685** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 71 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection
- **DRUG:** TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)

## Key facts

- **NCT ID:** NCT07653685
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-03
- **Primary completion:** 2027-06
- **Final completion:** 2028-12
- **Target enrollment:** 71 (ESTIMATED)
- **Last updated:** 2026-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07653685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07653685, "A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07653685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*